Quick Answer
Neuphoria Therapeutics Inc. reported Research And Development Expense of $9.01 million for the year ending 2025.
- Neuphoria Therapeutics Inc. showed a decrease of -4.4% in Research And Development Expense from 2024 to 2025.
- This data is from Neuphoria Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on September 29, 2025.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Neuphoria Therapeutics Inc.'s Research And Development Expense has grown by 54.5%.
- Historical annual values: Fiscal year 2025: $9.01 million | Fiscal year 2024: $9.42 million | Fiscal year 2023: $13.07 million | Fiscal year 2022: $16.00 million | Fiscal year 2021: $5.76 million | Fiscal year 2020: $5.83 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: